SINGAPORE, SINGAPORE, SINGAPORE, March 20, 2026 /EINPresswire.com/ -- As we navigate the sophisticated landscape of ...

CTI-REALM is Microsoft’s open-source benchmark that evaluates AI agents on real-world detection engineering. It measures whether an agent can take cyber threat intelligence (CTI) and produce validated ...

These launches come just days before RSA Conference 2026 (March 23--26, Moscone Center, San Francisco) the world's largest and most influential cybersecurity event, where Votal AI will showcase live ...

Open-source projects form much of the foundation of modern software, with many systems used in the industry relying on code written and maintained by volunteers or small teams. Those maintainers often ...

Whether you are looking for an immersive virtual girlfriend experience, an untethered roleplay partner, or just an uncensored ...

The Trade Desk (TTD 0.95%) built its reputation as the independent demand-side platform for the open internet. The company based its pitch on neutrality, transparency, and perform ...

This article introduces practical methods for evaluating AI agents operating in real-world environments. It explains how to ...

We’ve had a look around at what’s out there for 2026, focusing on places that offer a decent free api hosting experience. Whether you’re just starting out or need a solid place for a project, there ...

The project is described by its creators as a universal swarm-intelligence engine designed to run large-scale simulations in order to explore possible future scenarios. Instead of relying on a single ...

Anthropic’s Claude Opus 4.6 introduces "Adaptive Thinking" and a "Compaction API" to solve context rot in long-running agents. The model supports a 1M token context window with 76% multi-needle ...

Electronic health records (EHRs); insurance claims; patient registries; wearable tech: Never before has health data been so abundant. However, the United States continues to struggle with siloed ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...